Plain-English translation of NCT07253896 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether AK104, a new immunotherapy medication, works better when combined with chemotherapy and other targeted treatments for advanced colorectal cancer that has already spread to other parts of the body. The study focuses on a specific type of colorectal cancer called MSS (microsatellite stable). Researchers want to see if this medication combination can help people whose cancer stopped responding to their initial first-line treatment.
Advanced colorectal cancer that has spread often stops responding to first-line treatments like FOLFOX or CAPOX chemotherapy. This trial exists to see whether adding this new medication to a combination of chemotherapy and targeted drugs might give patients a better chance of controlling their cancer when it returns or progresses.
You likely qualify if…
You likely don't qualify if…
You would receive the new medication AK104 along with chemotherapy and either cetuximab or bevacizumab (other targeted drugs) as your second-line treatment. The study takes place at a single hospital in China and involves about 40 participants total. You would need to provide tumor tissue samples for testing and attend regular clinic visits for treatment, blood work, and imaging scans to monitor how well the medication is working.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Enrollment target
~40 participants
Started
January 2024
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xuefeng Fang, Dr
Second Affiliated Hospital, School of Medicine, Zhejiang University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.